Stock

Ascendis Pharma A/S (ASND)

NASDAQ · Healthcare · Biotechnology

Profile

Ascendis Pharma A/S

Ascendis Pharma A/S logo
Exchange
NASDAQ
Ticker
ASND
Sector
Healthcare
Industry
Biotechnology
Country
DK

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Key facts

Ascendis Pharma A/S: key facts

  • Ascendis Pharma A/S (NASDAQ: ASND) is a Biotechnology company in the Healthcare sector.
  • In fiscal 2025, Ascendis Pharma A/S reported revenue of 691.7M EUR and net income of -219.0M EUR.
  • Revenue grew 207.1% a year over the last 4 fiscal years.
  • Free cash flow was positive in 1 of the last 5 fiscal years.
  • Net income was positive in 0 of the last 5 fiscal years.
  • Over the last twelve months, revenue was 1.2B EUR and net income was 890.4M EUR.

MonkScore

Ascendis Pharma A/S's MonkScore

MonkScore

MonkScore range: 90–100

as of November 2026

Sector rank: 4 of 640 in Healthcare

How this score is madeDisclaimer

Pillar ranges

  • Growth90–100
  • Profitability90–100
  • Quality50–59
  • Market Conviction80–89
  • Safety70–79

The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–9 to 90–100.

Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.

Fundamentals

Figures from the statements

Ascendis Pharma A/S's annual figures and the last twelve months, in EUR. Last report: 30 September 2026.

FigureLast 12 monthsFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue1.2B EUR691.7M EUR363.6M EUR266.7M EUR51.2M EUR7.8M EUR
Gross profit1.1B EUR588.5M EUR319.4M EUR222.3M EUR39.0M EUR4.3M EUR
Operating income222.3M EUR-130.9M EUR-278.8M EUR-455.5M EUR-561.8M EUR-451.8M EUR
Net income890.4M EUR-219.0M EUR-378.1M EUR-481.4M EUR-583.2M EUR-383.6M EUR
Operating cash flow533.9M EUR51.8M EUR-306.2M EUR-467.4M EUR-495.7M EUR-417.6M EUR
Capital expenditure-17.0M EUR-8.2M EUR-1.4M EUR-2.4M EUR-14.5M EUR-24.2M EUR
Free cash flow516.9M EUR43.6M EUR-307.6M EUR-469.8M EUR-510.2M EUR-441.9M EUR
Total debt455.4M EUR871.4M EUR856.6M EUR743.1M EUR617.6M EUR209.9M EUR
Cash980.7M EUR615.8M EUR559.5M EUR392.2M EUR444.8M EUR446.3M EUR

Revenue growth a year

1-year
90.2%
3-year
138.2%
4-year
207.1%

Compound growth between fiscal years.

Peers

Similar companies

  • BeOne Medicines AGHKG:6160MonkScore range: 90–100
  • SK Biopharmaceuticals Co., Ltd.KRX:326030MonkScore range: 90–100
  • argenx SEEBR:ARGXMonkScore range: 90–100
  • Nxera Pharma Co., Ltd.TYO:4565MonkScore range: 90–100
  • Innovent Biologics, Inc.HKG:1801MonkScore range: 90–100
  • Camurus ABSTO:CAMXMonkScore range: 90–100
  • RemeGen Co., Ltd.HKG:9995MonkScore range: 90–100
  • ALK-Abelló A/SCPH:ALK-BMonkScore range: 80–89
See the full analysisAscendis Pharma A/S's exact MonkScore and pillar scores, in the MonkStreet app

Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click

MonkStreet provides research, not investment advice.

Page built on 16 November 2026.